Infliximab in the treatment of Crohn's disease

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 301-308

  Poggioli, Gilberto ^a   Laureti, Silvio ^a   Campieri, Massimo ^a   Pierangeli, Filippo ^a   Giochetti, Paolo ^a   Ugolini, Federica ^a   Gentilini, Lorenzo ^a   Bazzi, Piero ^a   Rizzello, Fernando ^a   Coscia, Maurizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Crohn's disease; Infliximab; Local injection; Perianal fistulas

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CYTOKINE; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; PLACEBO; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL ABSCESS; ABDOMINAL SURGERY; ANUS FISTULA; ASPERGILLOSIS; CELLULITIS; CHILL; CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE SEVERITY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ENTEROPATHY; EXPERIENCE; FACE EDEMA; FEVER; HEADACHE; HEART DISEASE; HISTOPLASMOSIS; HUMAN; INTESTINE FISTULA; LENGTH OF STAY; LISTERIOSIS; LOADING DRUG DOSE; LUNG DISEASE; LUPUS ERYTHEMATOSUS; LYMPHOMA; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; MYALGIA; NONHODGKIN LYMPHOMA; OPTIC NEURITIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PNEUMONIA; PRACTICE GUIDELINE; PRURITUS; RASH; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SERUM SICKNESS; SORE THROAT; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; URINARY TRACT INFECTION; URTICARIA; UTERINE CERVIX CANCER; VIRUS INFECTION;

EID: 34249979483     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.301     Document Type: Review

References (63)

1. Alderson JW, van Dinter Jr TG, Opatowsky MJ, et al. 2005. Disseminated aspergillosis following Infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. Med Gen Med, 7:7.
2. [ATS] American Thoracic Society, Centers for Disease Control and Prevention. 2000. Council of the infectious disease society of America, September 1999. Am J Respir Crit Care Med, 161:1376-95.
3. Baert F, Noman M, Vermeire S, et al. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med, 348:601-8.
4. Beets-Tan RG, Beets GL, van der Hoop AG, et al. 2001. Preoperative MR imaging of anal fistulas: does it really help the surgeon? Radiology, 218:75-84.
5. Bell SJ, Halligan S, Windsor ACJ, et al. 2003. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther, 17:187-93.
6. Bickston SJ, Lichtenstein GR, Arseneau KO, et al. 1999. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology, 117:1433-37.
7. Breese E, Michie C, Nicholls S, et al. 1994. Tumor necrosis alpha-producting cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology, 106:1455-66.
8. Brooklyn TN, Dunnill MG, Shetty A, et al. 2006. Infliximab for the treatment of Pyoderma Gangrenosum: a randomised, double blind, placebo controlled trial. Gut, 55:505-9.
9. Centocor Inc. 2005a. Product information (EU): Remicade 100mg powder for concentrate for solution for infusion (infliximab 100mg vial) [online]. Accessed 10 May 2005. URL: http://www.emea.eu.int.
10. Centocor Inc. 2005b. Product information (US): Remicade for IV injection (infliximab 100mg vial) [online]. Accessed 10 May 2005. URL: http://www.remicade.com.
11. Chen SC, Cummings OW, Hartley MP, et al. 2006. Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. Dig Dis Sci, 51:952-5.
12. Colombel JF, Loftus EV, Tremaine WJ, et al. 2004. The safety profile of Infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology, 126:19-31.
13. Cornillie F, Shealy D, D'Haens G, et al. 2001. Infliximab induces potent anti-inflammatory and local activity, but no systemic immune suppression in patients with Crohn's Disease. Aliment Pharmacol Ther, 15:463-73
14. de Ridder L, Escher JC, Bouquet J, et al. 2004. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr, 39:46-52.
15. Derkx B, Taminiau J, Radema S, et al. 1993. Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet, 342:173-4.
16. Enayati PJ, Papadakis KA. 2005. Association of ant-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol, 39:303-6.
17. Farrell RJ, Alshahli M, Jeen YT, et al. 2003. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology, 124:917-24.
18. Gupta G, Gelfand JM, Lewis JD. 2005. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology, 129:819-26.
19. Hale S, Lightman S. 2006. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine, 33:231-7.
20. Hanauer SB, Feagan BG, Lichtenstein GR, et al. 2002. Maintenance Infliximab for Crohn's Disease: the ACCENT I randomized trial. Lancet, 359:1541-9.
21. Hanauer SB. 2003. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflam Bowel Dis, 12(Suppl 1):S3-S9.
22. Jois RN, Leeder L, Gibb A, et al. 2006. Low-dose infliximab treatment for Ankylosing Spondylitis: clinically and cost-effective. Rheumatology (Oxford), 45:1566-9.
23. Kane SV, Reddy D. 2004. Infliximab does not increase the risk of abnormal Pap smears in women. Am J Gastroenterol, 99:S246.
24. Keane J, Gershon S, Wise RP, et al. 2001. Tubercolosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 345:1098-104.
25. Kleyn CE, Griffiths CE. 2006. Infliximab for the treatment of psoriasis. Expert Opin Biol Ther, 6:797-805.
26. Kugathasan S, Levy MB, Saeian K, et al. 2002. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol, 97:1408-14.
27. Lichtenstein GR, Olson A, Bao W, et al. 2002. Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn's disease patients: ACCENT I study results. Am J Gastroenterol, 97:S254.
28. Lichtenstein GR, Yan S, Bala M, et al. 2005. Infliximab mainteinance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology, 128:862-9.
29. Lichtiger S. 2001. Healing of perianal fistulae by local injection of antibody to TNF. Gastroenterology, 120(suppl):A3154.
30. Markham A, Lamb HM. 2000. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs, 59:1341-59.
31. Mitoma H, Horiuki T, Hatta N, et al. 2005. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology, 128:376-92.
32. Nicholls S, Stephens S, Braegger CP, et al. 1993. Cytokines in stools of children with inflammatory bowel disease or infective diarrhea. J Clin Pathol, 46:174-81.
33. Papadakis KA, Targan SR. 2000. Tumor necrosis factor: biologic and therapeutic inhibitors. Gastroenterology, 119:1148-57.
34. Poggioli G, Laureti S, Pierangeli F, et al. 2005. Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum, 48:768-74.
35. Poritz LS, Rowe WA, Koltun WA. 2002. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum, 45:771-5.
36. Present DH, Rutgeers P, Targan S, et al. 1999. Infliximab for the treatment of fistulas in patients with Crohn's Disease. N Engl J Med, 340:1398-405.
37. Reinecker HC, Steffen M, Witthoeft T, et al. 1993. Enhanced secretion of tumor necrosis factor-alpha IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's Disease. Clin Exp Immunol, 94:174-81.
38. Remicade (Infliximab). 2001. Prescribing information. In: Physician desk reference, 55th ed. Montvale,NJ: Thomson Healthcare, pp 1085-88.
39. Rispo A, Lembo G, Insabato L, et al. 2004. Successful treatment of therapy-resistant metastatic Crohn's disease with infliximab. Br J Dermatol, 150:1045-6.
40. Robinson DM, Keating GM. 2005. Infliximab: in ankylosing spondylitis. Drugs, 65:1283-91.
41. Rutgeers P, Van Assche G, Vermeire S.2004. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology, 126:1593-610.
42. Ruutgers P, Feagan BG, Lichtenstein GR, et al. 2004. Comparison of scheduled and episodic treatment strategies of Infliximab in Crohn's disease. Gastroenterology, 126:402-13.
43. Sachmechian A, Vasiliauskas E, Abreu M, et al. 2001. Malignancy following remicade therapy: incidence and characteristics. Gastroenterology, 120:A619.
44. Sandborn WJ, Fazio VW, Feagan BG, et al; American Gastroenterological Association Clinical Practice Committee. 2003. Technical Review of Perianal Crohn's Disease. Gastroenterology, 125:1508-30.
45. Sandborn WJ, Hanauer SB. 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis, 5:119-133.
46. Sands BE, Anderson FH, Bernstein CN, et al. 2004. Infliximab manteinance therapy for fistulizing Crohn's disease. N Engl J Med, 350:876-85.
47. Sands BE, Blank MA, Diamond RH, et al. 2006. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther, 23:1127-36.
48. Scallon BJ, Moore MA, Trihn H, et al. 1995. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine, 7:251-9
49. Schwartz DA, Wiersema MJ, Norton ID, et al. 2001. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology, 121:1064-72.
50. Siddiqui MAA, Scott LJ. 2005. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs, 65:2179-208.
51. Spencer JA, Chapple K, Wilson D, et al. 1998. Outcome after surgery for perianal fistula: predictive value of MR imaging. AJR Am J Roentgenol, 171:403-6.
52. Targan SR, Hanauer SB, Deventer SJ, et al. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med, 337:1029-35.
53. Thomas CW jr, Weinshenker BG, Sandborn WJ. 2004. Demyelination during anti-tumor necrosis factor alpha therapy with Infliximab for Crohn's disease. Inflamm Bowel Dis, 10:28-31.
54. Topstad DR, Panaccione R, Heine JA, et al. 2003. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum, 46:577-83.
55. Toy LS, Scherl EJ, Kornbluth A, et al. 2000. Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: a series of a newly described complication. Gastroenterology, 118(suppl):A569.
56. van Assche G, Vanbeckevoort D, Bielen D, et al. 2003. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol, 98:332-9.
57. van den Brande JMH, Hommes DW, Peppelenbosch MP. 2005. Infliximab induced T lymphocyte apoptosis in Crohn's disease. J Rheumatol Suppl, 74:26-30.
58. Vermeire S, Noman M, Van Assche G, et al. 2003. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology, 125:32-9.
59. Warris A, Bjorneklett A, Gaustad P. 2001. Invasive pulmonary aspergillosis associated with Infliximab therapy. N Engl J Med, 344:1099-100.
60. Weinberg AM, Rattan S, Lewis JD, et al. 2002. Strictures and response to Infliximab in Crohn's disease. Am J Gastroenterol, 97:S255.
61. Westhovens R, Rahman MU, Han C. 2005. Infliximab treatment results in a rapid improvement in all aspects of quality of life assessed by the sf-36 in patients with Rheumatoid Arthritis: results from the START trial [abstract]. Ann Rheum Dis, 64(Suppl. III):392, FRI0450.
62. Wiendl H, Hohlfeld R. 2002. Therapeutic approaches in multiple sclerosis: lessons fromfailed and interrupted treatment trials. Bio Drugs, 16:183-200.
63. Witthoft T, Ludwig D. 2005. Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany. Int J Colorectal Dis, 20:18-23.